Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERX-963 in Adults With Myotonic Dystrophy Type 1
NCT03959189Phase 1Completed
- Sponsor
- Expansion Therapeutics
- Start
- Jun 2019
- Primary completion
- Mar 2020
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of flumazenil in myotonic dystrophy type 1 (DM1) (2 arms), sponsored by Expansion Therapeutics. Primary endpoint: Incidence of Adverse Events, Serious Adverse Events, and Drug-related Adverse Events up to 57 days. Started Jun 2019; status: completed.
02
Drugs
flumazenil
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT03959189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959189.